DSM FOOD SPECIALTIES BV

Their core work

DSM Food Specialties is the biotechnology and food ingredients division of Royal DSM, a major Dutch multinational. They develop industrial enzymes, bio-based chemicals, and fermentation-derived food ingredients at commercial scale. In H2020, they serve as an industrial partner providing real-world manufacturing expertise and validation capacity to academic research consortia focused on metabolic engineering, biocatalysis, and bio-based value chains. Their participation bridges the gap between laboratory enzyme and cell factory research and actual industrial production.

What they specialise in

How they've shifted over time

In the first half of their H2020 participation (2015–2017), DSM focused on foundational biotechnology: enzyme engineering, protein secretion, biocatalysis, and analytical techniques — building the scientific base for industrial bioprocesses. From 2018 onward, their projects shifted decisively toward applied bio-manufacturing: modular cell factories (SHIKIFACTORY100), continuous downstream processing (CODOBIO), and synthetic biology for production (SynCrop). This trajectory shows a company moving from enabling research toward scalable, industrially deployable bio-production systems.

DSM is moving toward integrated, continuous bio-manufacturing platforms — partners seeking industrial-scale cell factory validation or bioprocess scale-up should take note.

How they like to work

DSM primarily joins consortia as an industrial partner or third party rather than leading them — they coordinated only 2 of 13 projects. Seven of their projects are MSCA training networks, reflecting a deliberate strategy of investing in early-stage researcher training while gaining first access to emerging talent and techniques. With 149 unique partners across 21 countries, they function as a hub connecting academic research to industrial application, making them a highly networked but selective collaborator.

DSM has collaborated with 149 unique partners across 21 countries, forming one of the densest industrial biotechnology networks in H2020. Their partnerships span top European universities and research institutes, with particularly strong ties to the Dutch, German, and Scandinavian biotech ecosystems.

What sets them apart

DSM brings something few academic or SME partners can: proven, large-scale fermentation and enzyme production infrastructure combined with deep regulatory knowledge for food and bio-based product markets. Their heavy involvement in MSCA training networks means they are embedded in the pipeline of emerging biotech talent across Europe. For consortium builders, DSM offers both industrial validation capacity and a direct route to market for bio-based innovations.

Highlights from their portfolio

• BIOFOREVER
  DSM's largest H2020 investment (EUR 1.5M) and one of only two projects they coordinated — a BBI demonstration project for converting forestry biomass into bio-based products.
• SHIKIFACTORY100
  Ambitious cell factory project targeting 100 compounds from a single metabolic pathway, with DSM's largest participant funding (EUR 885K) — represents their strategic shift toward modular bio-manufacturing.
• SUPERB
  Their most recent coordination role (2020), exploring structural proteins for biomedical materials — a departure from food/chemicals that signals diversification into health-adjacent biomaterials.